VATE — INNOVATE Corp. · 2026-09-09 · Verdict: PASS · Conviction 4

Price $7.03 (screen close, 2026-09-09) · Mkt cap $95.9M · EV ~$644M · EV/normalised after-tax profit 10.9x · LTM FCF ~breakeven · Net debt $538.6M · ADV $1.4M Sources read: 10-K 2026-03-26 (Items 1, 1A, 7), 10-Q 2026-08-06 (Item 2), DEF 14A 2026-04-28, 8-Ks 2026-07-08, 08-03, 08-06, 08-10, 08-18, 09-02, Form 4s (12m), Q2 2026 earnings release (8-K 2026-08-06, EX-99.1).

Desk stats

• Revenue trend. FY2025 $1,246.0M vs $1,107.1M, +12.5%, essentially all Infrastructure ($1,210.3M vs $1,071.6M) (10-K 2025, Item 7). Q2 2026 $421.6M vs $242.0M, +74.2%; Infrastructure +77.6% on the timing and size of large commercial structural steel projects plus favourable cost-to-complete revisions. Volume and mix, not price, and not acquired (10-Q, Item 2).
• Normalised after-tax operating profit. LTM (Jul-25 to Jun-26) GAAP income from operations = $28.7M + $44.5M − $8.3M = $64.9M. Add realignment and exit costs $3.0M, debt refinancing costs $4.8M, acquisition and disposition costs $3.7M, facility commissioning costs $3.0M; deduct net other operating income $0.8M (Adjusted EBITDA reconciliations, 10-K Item 7 and 10-Q Item 2). No impairment reported. Normalised operating profit $78.6M, taxed at 25% = $59.0M, against $48.7M on the GAAP figure. The 25% rate flatters: H1 2026 tax was $16.0M on $11.3M of pre-tax income because Section 382 caps NOL use (10-Q, Item 2).
• EV / normalised after-tax profit. 13,641,866 shares at $7.03 = $95.9M. Principal indebtedness on a continuing-operations basis was $626.4M at 30 June 2026 (carrying $553.9M current plus $62.1M non-current); cash $87.8M; redeemable Series A-3/A-4 preferred carried at $9.7M. EV ≈ $644M ($658M including $13.5M of non-controlling interests). 10.9x, not the screen's 3.3x.
• Leverage. Net debt $538.6M / normalised LTM Adjusted EBITDA $110.3M ($67.2M + $66.0M − $22.9M) = 4.9x. The structural number matters more: $505.2M sits at the holdco against $1.5M of holdco cash, all maturing within twelve months, while the EBITDA sits at DBMG, a restricted non-guarantor subsidiary carrying ~$70M of its own debt on $123.2M of LTM Adjusted EBITDA (10-Q, Liquidity).
• Growth sustainable? Organic, not bought; not cash-backed (H1 2026 operating cash flow $20.9M against $66.0M of Adjusted EBITDA and $19.9M of capex); no guidance; and it is being sold. DBMG goes to IES Holdings for $650M of base consideration, expected to close in Q4 2026 (8-K 2026-08-10, Item 1.01).
• What the screen got wrong. It read only the non-current debt tag ($62.1M) and missed the $553.9M classified as current, printing "net cash $26M" and a $70M EV instead of $538.6M of net debt and a $644M EV. It took capex as $0.5M when FY2025 capex was $26.1M, producing a 152% FCF yield. It saw none of the going-concern paragraph, the paid-in-kind interest, the unpaid preferred redemption, the $243.2M stockholders' deficit, or the signed sale of the only business that earns anything.

1. What the business actually does

A holding company with three segments (10-K, Item 1). Infrastructure is DBM Global, a top-tier US structural steel fabricator and erector (Schuff, Banker Steel, GrayWolf, DBM Vircon, Aitken), 12 fabrication shops, FY2025 revenue $1,210.3M. Life Sciences is Pansend: 85% of R2 Technologies (Glacial skin-cooling devices, $2.2M of Q2 revenue) and 44.6% of MediBeacon, whose transdermal kidney-function system was FDA-approved in January 2025. Spectrum was 257 low-power and Class A TV stations. Everything else is corporate overhead and debt.

2. Why it looks mispriced, and why the edge case is not real

There is no edge case. The cheapness is an artefact of one XBRL debt tag. Include the $553.9M of current debt and the equity is a thin residual on a balance sheet with a $243.2M stockholders' deficit, under "substantial doubt about the Company's ability to continue as a going concern" (10-Q, Going Concern). Interest due 1 August 2026 on the 10.50% Senior Secured Notes and 9.5% Convertible Notes was paid in kind, lifting principal to $400.9M and $58.9M and conserving $19.0M of cash (8-K 2026-08-03). On 30 June 2026 the preferred holder demanded redemption and the Company "did not have sufficient legally available funds" to pay (10-Q, Item 2). Those are not the disclosures of a mispriced compounder.

3. Unit economics

DBMG is genuinely good and genuinely improving: Q2 gross margin 18.5%, up ~60bp; Adjusted EBITDA margin 11.8%, up ~350bp; backlog $1.9B reported and $2.7B adjusted, a record (Q2 release). But 59.8% of backlog sits in five contracts, the two largest customers were 22.1% of 2025 revenue, and part of the H1 margin gain came from "changes in the estimate of the cost to complete those projects", which is cumulative catch-up, not run rate. Cash conversion is poor: FY2025 operating cash flow of $146.6M was a working-capital inflow, and H1 2026 turned $66.0M of Adjusted EBITDA into $1.0M of free cash. R2 shrank (H1 revenue $3.8M vs $6.3M) "due to liquidity constraints".

4. Balance sheet and capital allocation

Corporate debt at 30 June 2026: $379.3M of 10.50% notes, $56.0M of converts, a $49.7M CGIC note at 16%, and a $20.0M revolver, all current, against $1.5M of holdco cash (10-Q). R2 owes Lancer Capital $50.9M at a 17% effective rate, secured by a first lien on all of R2's assets (10-K, Item 1A). Lancer, controlled by chairman Avram Glazer, owns 49.9% of the stock and is also a lender and noteholder (DEF 14A, ownership and related parties). On 10 August 2026 the Company opened a $31M ATM with Jefferies, a third of the market cap, the same week it signed the DBMG sale. Insiders bought nothing on the open market in twelve months; the only Form 4s are grants and tax withholding, including 133,511 shares to the interim CEO on 11 August 2026.

5. Management: said versus did

The chairman called Q2 "a strong quarter" and the interim CEO said the Company remains "focused on strengthening our balance sheet" (Q2 release). What it did: paid interest in kind, failed to redeem its preferred, opened an ATM, and sold both operating businesses under covenant compulsion. The 10-K is explicit that the DBMG sale process became mandatory when the September 2025 asset-sale milestone was missed (10-K, Item 1).

6. Valuation

This is a liquidation, not a multiple. IES pays $650M base for DBMG; INNOVATE's 91.21% share is $453M cash plus $140M of IES stock, plus $35M cash for a Section 338 election, about $628M, less DBMG's ~$70M facility, transaction costs and cash tax on a taxable sale (8-K 2026-08-10). Against that stand $479.8M of senior debt and the $49.7M CGIC note, both accreting. Base: the Company's own words, that assets will consist of net proceeds "of which the Company expects there to be none", plus the 25% Broadcasting stake, Life Sciences, and an option on 15% more of HC2. CONX's $75M commitment for 75% implies about $25M for INNOVATE's 25%, and no cash is received unless the CONX affiliate exercises its 80.1% option (8-K 2026-09-02). Call the stub $30M to $60M against a $95.9M cap, before $31M of ATM dilution. Bear: closing slips past the February 2027 note maturity with the IES stock still locked up, forcing another refinancing or a restructuring; equity near zero. Bull: favourable closing adjustments plus MediBeacon commercialising take the stub to $150M. Reverse DCF: at $7.03 the market implies roughly $96M of residual value, pre-dilution, after a debt stack that management says will absorb all cash proceeds. The price implies the Company is wrong about its own waterfall.

7. Catalysts and timeline

DBMG closing, guided to Q4 2026; the Schedule 14C information statement, which should show the proceeds waterfall; the 1 February 2027 note maturity; ATM issuance volume.

8. Risks and pre-registered kill criteria

1. The Schedule 14C or an 8-K discloses net cash at the holdco above $100M after full repayment of the notes, converts, revolver and CGIC note.
2. The 10.50% 2027 Senior Secured Notes are redeemed in full in cash and the going-concern qualification is removed.
3. MediBeacon raises at a valuation implying more than $150M for Pansend's 44.6% stake.
4. Confirming the PASS: another paid-in-kind election on the February 2027 coupon, or ATM issuance above 2M shares.

9. Verdict and summary

PASS, conviction 4. INNOVATE screens at 3.3x after-tax profit and a 152% free-cash yield only because the screen read one XBRL tag that captured $62.1M of non-current debt and missed the $553.9M sitting in current liabilities. Real enterprise value is about $644M against $59M of normalised after-tax profit, or 10.9x, on a balance sheet with a $243.2M stockholders' deficit, a going-concern qualification, interest being paid in kind, and a preferred redemption the Company could not fund. The operating business is real and improving, with DBM Global printing a record quarter on a $2.7B adjusted backlog, but it has already been sold to IES Holdings for $650M, and INNOVATE has told investors in writing that after required debt repayments it expects none of those proceeds to be left. What you buy at $7.03 is a stub: a 25% non-cash stake in a low-power TV broadcaster, a cash-burning aesthetics device business whose assets are pledged to the 49.9% shareholder, and 44.6% of a pre-revenue kidney diagnostics company, against a $31M at-the-market offering already open. That is a workout with a controlling insider on both sides of the capital structure, not a quality-growth small cap.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.